Utilization of MRT in the Clinical Setting

Utilizing MRT (measurable residual disease) in the clinical setting has become a reality that is now featured as an endpoint in clinical trials. The first fundamental step is to codify and reach consensus on the definitions of CR (complete remission) and PR (partial remission), as well as determine the relevance of PR. Additionally, the incorporation of molecular biology and genetic mutations into response definitions is necessary to improve treatment decision-making. This would enable the rationing of selected agents for patients with measurable residual disease, potentially leading to personalized therapies and the role of bone marrow transplantation in improving patient outcomes.